Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.70 |
| ▸ | GCGR | P47871 | 6/20 | 0.70 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.63 |
| ▸ | NPY2R | P49146 | 1/20 | 0.63 |
| ▸ | NPY4R | P50391 | 1/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.63 |
| ▸ | CALCR | P30988 | 3/20 | 0.63 |
| ▸ | NMBR | P28336 | 1/20 | 0.62 |
| ▸ | GRPR | P30550 | 1/20 | 0.62 |
| ▸ | GIPR | P48546 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31379433 | 0.94 | NMBR (0.70) | GLP1RGCGRC5AR1CALCRNMBR | |
| SCHEMBL29464570 | 0.94 | NPY2R (0.71) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182829 | 0.92 | GLP1R (0.73) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL23273229 | 0.92 | NMBR (0.69) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL4956503 | 0.91 | GLP1R (0.61) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL29965030 | 0.91 | C5AR1 (0.74) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL29755703 | 0.91 | GLP1R (0.72) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL30658246 | 0.90 | GLP1R (0.79) | GLP1RGCGRKEAP1NPY1RNPY2R | |
| SCHEMBL30932062 | 0.90 | GLP1R (0.74) | GLP1RGCGRC5AR1KEAP1NPY1R | |
| SCHEMBL29737187 | 0.90 | C5AR1 (0.75) | GLP1RGCGRC5AR1KEAP1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250026803-A1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-23 | — | — | US | disclosed |
| US-12134636-B2 | Immunoglobulins and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-05 | — | — | US | disclosed |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-08-22 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2023-07-20 | — | — | US | disclosed |
| CN-110101840-B | Application of combination of neuropeptide B23/W23 and morphine in preparation of analgesic drugs | 徐州医科大学 | 2023-03-28 | — | — | CN | disclosed |
| US-11401315-B2 | Immunoglobulins and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-02 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GLP1R 1209/4885GCGR 1242/4885C5AR1 316/4885 |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | GLP1R 55/4885GCGR 3000/4885C5AR1 475/4885 |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | VIP, NGLY1, SPPL2B | GLP1R 146/4885GCGR 2221/4885C5AR1 160/4885 |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | GLP1R 146/4885GCGR 2221/4885C5AR1 160/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GLP1R 1209/4885GCGR 1242/4885C5AR1 316/4885 |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | GLP1R 146/4885GCGR 2221/4885C5AR1 160/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | GLP1R 553/4885GCGR 648/4885C5AR1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.